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Controlling blood lipids is a major public health challenge of our time. The pleiotropic
hormone-like polypeptide fibroblast growth factor 21 (FGF21) was recently recognized
as a potent modulator of lipid and glucose metabolism and a promising treatment strategy
for obesity related metabolic disorders, including dyslipidemia. A cost effective and
practical alternative to the administration of recombinant FGF21 is to stimulate
endogenous FGF21 production through diet. Our research identified (R)--lipoic acid
(LA), a naturally occurring enzyme cofactor and dietary molecule found in green leafy
vegetable and red meat, as an inducer of FGF21 expression. LA stimulated FGF21
production, demonstrated by a 3-fold increase in circulating FGF21, in the obese animal
by upregulating hepatic Fgf21 expression. Concomitantly, feeding LA to dyslipidemic
obese rats corrected high blood triacylglycerol levels and lowered abdominal adiposity by
stimulating liver gene expression of peroxisome proliferator-activated receptor 
(PPAR target genes involved in lipid disposal and conjointly decreasing de novo lipid
synthesis as a two-sided complementary mechanism to mitigate lipid burden. Since the

metabolic effects of LA mimic those of FGF21, we posit that FGF21 mediates the
beneficial phenotype evoked by LA and sought to determine how LA and its reduced
form, (R)--dihydrolipoic acid (DHLA), induce the Fgf21 promoter. To that end, we
employed HepG2 hepatocellular carcinoma cells under fed and starved states and in the
presence of LA and DHLA. Serum withdrawal markedly induced FGF21 mRNA
abundance from 24 to 48 hours after serum removal. Both LA and DHLA induced
FGF21 mRNA levels at 36 hours after serum removal when compared to vehicle control.
To further determine the regulatory mechanism of FGF21 transcription, we have begun
to develop the FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) assay
coupled to qPCR to isolate and identify active regulatory promoter regions. We designed
and validated a collection of primers specific for human FGF21 promoter that will allow
the functional mapping of a 4,573-bp 5’ UTR region.
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CHAPTER 1

INTRODUCTION

Controlling blood lipids is a major public health challenge of our time, when over
100 million Americans are overweight or obese. The National Cholesterol Education
Program considers hypertriglyceridemia (i.e. fasting blood triglyceride (TG) levels 150
mg/dl or 1.5 mM) to be an independent risk factor for coronary heart disease [1].
Lowering blood TG translates into substantial cardiovascular benefits. For instance, a
29% reduction in TG is associated with a 22% reduction in coronary heart disease
mortality [2]. Hypertriglyceridemia is also a major risk factor for liver disease and type-2
diabetes [3]. Despite significant advances in treatment ~65 million Americans have
hypertriglyceridemia.
Conventional therapy for hypertriglyceridemia includes dietary weight loss and
exercise, dietary supplementation with fish oil or niacin, and drug intervention, which
may include fibrates or combined therapy with statins when LDL-cholesterol is elevated
(Table 1.1). As the country is facing an obesity epidemic, the likelihood of controlling
hypertriglyceridemia by weight loss – on an epidemiological scale – is proving elusive at
best. Although some improvement is noted with drug therapies, serious associated side
effects remain a concern. Thus, clinicians must administer lipid-lowering drugs carefully,
especially in patients with renal and hepatic dysfunction, and in the elderly. This grim
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picture means that an ever-growing number of hypertriglyceridemic patients will not be
adequately treated for their lipid disorder and remain at elevated risk for cardiovascular
disease, liver disease, and type-2 diabetes. There is, therefore, a critical need to identify
therapeutic agents that would lessen hypertriglyceridemia and also be safe and relatively
inexpensive.

Fibroblast growth factor 21 (FGF21)
The endocrine hormone fibroblast growth factor 21 (FGF21) is a pleiotropic
hormone-like protein that encoded by human FGF21 gene. FGF21 was classified as a
fibroblast growth factor based on its structure, since it contains a typical structure domain
of FGF and shares 10–30% sequence identity with other FGFs, mostly FGF19 [4]. It has
long been detected as a powerful modulator of lipid and glucose metabolism and a
promising treatment strategy for obesity related metabolic disorders [5,6,7,8]. FGF21 is
expressed in liver, pancreas, adipose and muscle tissue [9,10]. FGF21 functions through
binding to cell-surface FGF receptor (FGFR)/-Klotho complex in target tissues [11,12]
(Fig. 1.1. & 1.2.). Induction of liver FGF21 expression is required for normal activation
of lipid oxidation and TG catabolism [5,13]. Conversely, genetic deletion of FGF21
results in fatty liver and hypertriglyceridemia [13]. The administration of FGF21 to obese
rats and mice increases fat utilization and energy expenditure, and reduces plasma TG,
glucose, insulin, and hepatic TG [5,6,7].
The liver secretes TAG as very-low density lipoprotein (VLDL) from a cytosolic
TAG pool whose availability limits VLDL assembly and stability (Fig. 1.3.). In the TAG
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synthetic pathway glycerol-3-phosphate acyltransferase (GPAT) catalyzes the ratelimiting acylation of glycerol-3-phosphate (glycerol-3-P) with acyl-CoA generating
lysophosphatidic acid (LPA). Subsequent reactions, catalyzed by LPA acyltransferase and
diacylglycerol acyltransferase (DGAT), generate diacylglycerol and finally TAG. Newly
synthesized TAG is either deposited in intracellular lipid vacuoles or exported in VLDL
particles. Reduced hepatic TG administrated by FGF21 to obese rats and mice is
accompanied by a decrease in lipogenic gene expression of GPAT1, DGAT2, ACC1, FAS,
stearoyl-CoA desaturase-1, and fatty acid elongase-6, and stimulation of PPARα lipolytic
target genes [6,7].
Recombinant FGF21 (rFGF21) is currently being investigated as therapeutic
against high blood lipids and type-2 diabetes [14]. However, the high costs of producing
rFGF21 and the mode of delivery by injection are important limitations to its wide
therapeutic use. A cost effective and practical alternative is to stimulate endogenous
FGF21 production through diet.

(R)--lipoic acid
(R)-α-Lipoic acid (LA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic
acid, is a naturally occurring dithiol compound found in green-leafy vegetables and red
meats. LA is synthesized enzymatically from octanoic acid in most prokaryotic and
eukaryotic microorganisms as well as plant and animal mitochondria [15]. It contains one
chiral center and has both R- and S-enantiomeric forms (Fig. 1.4.). Beside synthesized,
LA is also absorbed from dietary sources such as muscle meats, heart, kidney, and liver,
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and to a lesser degree, fruits and vegetables [16]. However, the amounts of LA consumed
in the traditional Western diet is not appreciable; therefore, dietary supplements are the
primary sources of LA (typically ranging from 50 to 600 mg), and most positive health
outcomes reported in the literature derived from LA supplements.
Growing evidences show that orally supplied LA elicits biochemical activities
with potential therapeutic value against a host of pathophysiological conditions, including
diabetic polyneuropathies, age-associated cardiovascular, cognitive, and neuromuscular
deficits [15]. LA has been described as a potent biological antioxidant and a
detoxification agent (Fig. 1.5.). Many cases indicate that LA was not directly exerting its
anti-oxidation abilities but by modulating glutathione (GSH) via nuclear factor
(erythroid-derived 2)-like 2 (transcription factor Nrf2), and then plays an important role
for protection against ischemic damage [17]. Besides, LA/DHLA has also been reported
to improve age-associated cardiovascular, cognitive, and neuromuscular deficits, and has
been implicated as a modulator of various inflammatory signaling pathways [18-23]. This
impressive array of cellular and molecular functions has piqued considerable interest
among the lay public and the research community for the use of LA both as a nutritive
supplement and as a pharmacotherapy.
Studies done by Diesel et al. showed that LA/DHLA mediates insulin pathway
and glucose uptake by modulating the IR/PI3K/Akt pathway at different levels (Fig. 1.6.).
The mediation of LA with the insulin-signaling cascade via different levels of regulatory
components proved beneficial in animal studies due to the improvements made in skeletal
muscle glucose uptake, whole-body glucose tolerance, and insulin resistance [26,27].
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Beyond that, improvements in glucose handling were also detected in clinical trials both
intravenously and orally with type 2 diabetics taking LA [27-29].
Recently, the TG-lowering properties of dietary LA have been recognized, first in
laboratory animals [30,31] then in clinical trials [32,33]. Despite these reports, the
mechanism by which LA regulates blood TG is not well known and the degree to which
LA can improve severe hypertriglyceridemia poorly documented.

6

REFERENCES
[1] NCEP, Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of
High Blood Cholesterol In Adults (Adult Treatment Panel III), Jama 285 (2001) 24862497.
[2] H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, F.H. Faas,
E. Linares, E.J. Schaefer, G. Schectman, T.J. Wilt, J. Wittes, Gemfibrozil for the
secondary prevention of coronary heart disease in men with low levels of high-density
lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol
Intervention Trial Study Group, N Engl J Med 341 (1999) 410-418.
[3] E.S. Ford, W.H. Giles, W.H. Dietz, Prevalence of the metabolic syndrome among US
adults: findings from the third National Health and Nutrition Examination Survey, Jama
287 (2002) 356-359.
[4]. Nishimura, T. et al. (2000) Identification of a novel FGF, FGF-21, preferentially
expressed in the liver. Biochim. Biophys. Acta 1492, 203–206
[5] A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J.
Galbreath, G.E. Sandusky, L.J. Hammond, J.S. Moyers, R.A. Owens, J. Gromada, J.T.
Brozinick, E.D. Hawkins, V.J. Wroblewski, D.S. Li, F. Mehrbod, S.R. Jaskunas, A.B.
Shanafelt, FGF-21 as a novel metabolic regulator, J Clin Invest 115 (2005) 1627-1635.
[6] T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, Y. Chen, D.E. Moller,
A. Kharitonenkov, Fibroblast growth factor 21 corrects obesity in mice, Endocrinology
149 (2008) 6018-6027.
[7] J. Xu, D.J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits, S. Vonderfecht, R.
Hecht, Y.S. Li, R.A. Lindberg, J.L. Chen, D.Y. Jung, Z. Zhang, H.J. Ko, J.K. Kim, M.M.
Veniant, Fibroblast growth factor 21 reverses hepatic steatosis, increases energy
expenditure, and improves insulin sensitivity in diet-induced obese mice, Diabetes 58
(2009) 250-259.
[8] E.D. Berglund, C.Y. Li, H.A. Bina, S.E. Lynes, M.D. Michael, A.B. Shanafelt, A.
Kharitonenkov, D.H. Wasserman, Fibroblast growth factor 21 controls glycemia via
regulation of hepatic glucose flux and insulin sensitivity, Endocrinology 150 (2009)
4084-4093.
[9] T. Nishimura, Y. Nakatake, M. Konishi, N. Itoh, Identification of a novel FGF, FGF21, preferentially expressed in the liver, Biochim Biophys Acta 1492 (2000) 203-206.
[10] E.S. Muise, B. Azzolina, D.W. Kuo, M. El-Sherbeini, Y. Tan, X. Yuan, J. Mu, J.R.
Thompson, J.P. Berger, K.K. Wong, Adipose fibroblast growth factor 21 is up-regulated
by peroxisome proliferator-activated receptor gamma and altered metabolic states, Mol
Pharmacol 74 (2008) 403-412.
[11] Y. Ogawa, H. Kurosu, M. Yamamoto, A. Nandi, K.P. Rosenblatt, R. Goetz, A.V.
Eliseenkova, M. Mohammadi, M. Kuro-o, BetaKlotho is required for metabolic activity
of fibroblast growth factor 21, Proc Natl Acad Sci U S A 104 (2007) 7432-7437.
[12] M. Suzuki, Y. Uehara, K. Motomura-Matsuzaka, J. Oki, Y. Koyama, M. Kimura, M.
Asada, A. Komi-Kuramochi, S. Oka, T. Imamura, betaKlotho is required for fibroblast
growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c,
Molecular endocrinology 22 (2008) 1006-1014.
[13] M.K. Badman, P. Pissios, A.R. Kennedy, G. Koukos, J.S. Flier, E. Maratos-Flier,

7

Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of
hepatic lipid metabolism in ketotic states, Cell Metab 5 (2007) 426-437.
[14] Y. Zhao, J.D. Dunbar, A. Kharitonenkov, FGF21 as a therapeutic reagent, Advances
in experimental medicine and biology 728 (2012) 214-228.
[15] K.P. Shay, R.F. Moreau, E.J. Smith, A.R. Smith, T.M. Hagen, Alpha-lipoic acid as a
dietary supplement: molecular mechanisms and therapeutic potential, Biochim. Biophys.
Acta 1790 (2009) 1149–1160.
[16] S. Akiba, S. Matsugo, L. Packer, T. Konishi, Assay of protein-bound lipoic acid in
tissues by a new enzymatic method, Anal. Biochem. 258 (1998) 299–304.
[17] F. Kilic, G.J. Handelman, K. Traber, K. Tsang, L. Packer, J.R. Trevithick, Modelling
cortical cataractogenesis XX. In vitro effect of alpha-lipoic acid on glutathione
concentrations in lens in model diabetic cataractogenesis, Biochem. Mol. Biol. Int. 46
(1998) 585–595.
[18] A.R. Smith, S.V. Shenvi, M. Widlansky, J.H. Suh, T.M. Hagen, Lipoic acid as a
Potential therapy for chronic diseases associated with oxidative stress, Curr. Med. Chem.
11 (2004) 1135–1146.
[19] J. Liu, E. Head, A.M. Gharib, W. Yuan, R.T. Ingersoll, T.M. Hagen, C.W. Cotman,
B.N. Ames, Memory loss in old rats is associated with brain mitochondrial decay and
RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or Ralpha- lipoic
acid, Proc. Natl. Acad. Sci. USA 99 (2002) 2356–2361.
[20] J.H. Suh, S.V. Shenvi, B.M. Dixon, H. Liu, A.K. Jaiswal, R.M. Liu, T.M. Hagen,
Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis,
which is reversible with lipoic acid, Proc. Natl. Acad. Sci. USA 101 (2004)
3381–3386.
[21] J.K. Lodge, M.G. Traber, L. Packer, Thiol chelation of Cu2+ by dihydrolipoic acid
prevents human low density lipoprotein peroxidation, Free Radic. Biol. Med. 25 (1998)
287–297.
[22] B. Anuradha, P. Varalakshmi, Protective role of DL-alpha-lipoic acid against
mercury-induced neural lipid peroxidation, Pharmacol. Res. 39 (1999) 67–80.
[23] D. Han, C.K. Sen, S. Roy, M.S. Kobayashi, H.J. Tritschler, L. Packer, Protection
against glutamate-induced cytotoxicity in C6 glial cells by thiol antioxidants, Am. J.
Physiol. 273 (1997) R1771–R1778.
[24] A.J. Michels, N. Joisher, T.M. Hagen, Age-related decline of sodium-dependent
ascorbic acid transport in isolated rat hepatocytes, Arch. Biochem. Biophys. 410 (2003)
112–120.
[25] J.H. Suh, E.T. Shigeno, J.D. Morrow, B. Cox, A.E. Rocha, B. Frei, T.M. Hagen,
Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)(alpha)-lipoic acid, FASEB J. 15 (2001) 700–706.
[26] R.S. Streeper, E.J. Henriksen, S. Jacob, J.Y. Hokama, D.L. Fogt, H.J. Tritschler,
Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin resistant
skeletal muscle, Am. J. Physiol. 273 (1997) E185–E191.
[27] S. Jacob, R.S. Streeper, D.L. Fogt, J.Y. Hokama, H.J. Tritschler, G.J. Dietze, E.J.
Henriksen, The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose
metabolism in insulin-resistant rat skeletal muscle, Diabetes 45 (1996) 1024–1029.
[28] S. Jacob, E.J. Henriksen, A.L. Schiemann, I. Simon, D.E. Clancy, H.J. Tritschler,
W.I. Jung, H.J. Augustin, G.J. Dietze, Enhancement of glucose disposal in patients with

8

type 2 diabetes by alpha-lipoic acid, Arzneimittelforschung 45 (1995) 872–874.
[29] T. Konrad, P. Vicini, K. Kusterer, A. Hoflich, A. Assadkhani, H.J. Bohles, A. Sewell,
H.J. Tritschler, C. Cobelli, K.H. Usadel, alpha-Lipoic acid treatment decreases serum
lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese
patients with type 2 diabetes, Diabetes Care 22 (1999) 280–287.
[30] M.S. Kim, J.Y. Park, C. Namkoong, P.G. Jang, J.W. Ryu, H.S. Song, J.Y. Yun, I.S.
Namgoong, J. Ha, I.S. Park, I.K. Lee, B. Viollet, J.H. Youn, H.K. Lee, K.U. Lee,
Antiobesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMPactivated protein kinase, Nat. Med. 10 (2004) 727–733.
[31] J.A. Butler, T.M. Hagen, R. Moreau, Lipoic acid improves hypertriglyceridemia by
stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion,
Arch. Biochem. Biophys. 485 (2009) 63–71.
[32] R.G. Alken, D. Koegst, G. Fries, Treatment of lipid metabolic disorders using 5(1,2-dithiolan-3-yl)valeric acid (alpha-lipoic acid) or its physiologically compatible salts,
US Patent # 6,518,300 B2 (2003).
[33] Y. Zhang, P. Han, N. Wu, B. He, Y. Lu, S. Li, Y. Liu, S. Zhao, L. Liu, Y. Li,
Amelioration of lipid abnormalities by alpha-lipoic acid through antioxidative and antiinflammatory effects, Obesity 19 (2011) 1647–1653.

9

Table 1.1. Therapies for managing dyslipidemia
Therapy

TG

LDL-C

HDL-C

Possible side effects

Fibrates

 40-60%

 5-30%

 15-25%

Myopathy, rhabdomyolysis,
elevated liver enzymes

Statins

 20-40%  18-55%

 5-15%

Myopathy, rhabdomyolysis,
elevated liver enzymes

Niacin

 30-50%

 5-25%

 20-30%

Flushing, worsening glycemia,
elevated liver enzymes

Fish oil

 30-50%

 5-10%

 5-10%

Fishy aftertaste, gastrointestinal
upset

TG, triglyceride; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol
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Figure 1.1. The mechanism of FGF21 receptor activation. (a). The FGFR/KLB
receptor complex is silent without FGF21. (b). FGF21 binds to KLB via its C-terminus,
then causes a conformational change in FGFR or FGF21 or both, which later allow
FGF21 binds to FGFR via its N-terminus. The binding of FGF21 with FGFR/KLB
receptor complex will trigger a following downstream signaling and a series of cellular
responses. [Figure source: Kharitonenkov, Larsen et al. 2010].
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Figure 1.2. Effects of FGF21 on hepatocytes and adipocytes in animal models. a).
FGF21 binds to FGFR/KLB receptor complex while β-Klotho stimulating glucose uptake
in differentiated adipocytes through GLUT1 induction. b). Fasting stimulates both
FGF21 gene expression in hepatocytes and the circulating levels of FGF21 protein which
can improve the lipolysis in adipocytes and ketogenesis and gluconeogenesis in liver
directly induced by PPARα. [Figure modified from: P Iglesias, et al. 2012].
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Figure 1.3. Liver triglyceride (TAG) synthesis. ACC, acetyl-CoA carboxylase; ACS,
Acyl-CoA synthase; AMPK, AMP-activated protein kinase; ATP:CL, ATP:citrate lyase;
ChREBP, carbohydrate responsive element binding protein; DGAT, diacylglycerol Oacyltransferase; FA:BP, fatty acid binding protein; FAS, fatty acid synthase; GK,
glucokinase; G3PDH, glycerol-3-phosphate dehydrogenase; GPAT, glycerol-3-phosphate
acyltransferase; HSL, hormone sensitive lipase; LXR, liver X receptor; PK, pyruvate
kinase; PP2A, protein phosphatase 2A; PUFA, polyunsaturated fatty acid; SREBP-1c,
sterol regulatory element binding protein-1c; VLDL, very low density lipoprotein; X5P,
xylulose-5-phosphate.
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Figure 1.4. LA and its reduced form, DHLA. DHLA is naturally generated in
the body after the consumption of LA. The presence of an asymmetric carbon
yields two enantiomers, R-LA (R-DHLA) and S-LA (S-DHLA), during organic
synthesis. Only the naturally occurring R-LA (R-DHLA) enantiomer is bound
covalently to the epsilon amino group of lysine residues of mitochondrial
multienzyme complexes.
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Figure 1.5. Proposed action of LA for induction of Phase II genes through Nrf2mediated transcription. LA may oxidize critical thiols on the Keap1 dimer to halt Nrf2
degradation, and to prevent Keap1 from binding newly synthesized Nrf2. LA may also
activate protein kinase signaling pathways that cause phosphorylation of Nrf2 on Ser40.
This is the event that allows it to dissociate from Keap1 [24, 25]. Nrf2 can then localize
to the nucleus and bind to the ARE, promoting transcription of genes for the Phase II
detoxification response. [Figure source: K.P. Shay et al. et al. 2009].
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Figure 1.6. Role of lipoic acid in IR/PI3K/Akt-dependent activation of glucose
uptake in skeletal muscle. Diesel et al. IR: insulin receptor. PTPB1: protein tyrosine
phosphatase B1. IRS1: insulin receptor substrate 1. AMPK: AMP-activated protein
kinase. PIP3: PtdIns-3, 4, 5-P3. PDK1: PtdIns-dependent kinase 1. Rab-GAP: GTPaseactivating protein. [Figure source: K.P. Shay et al. et al. 2009].
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CHAPTER 2

REVERSAL OF OBESITY-INDUCED
HYPERTRIGLYCERIDEMIA BY (R)-α-LIPOIC ACID
IN ZDF (fa/fa) RATS

INTRODUCTION
Controlling blood lipids is a major public health challenge of our time, when over
1.4 billion adults worldwide are overweight or obese. Hypertriglyceridemia, defined as
abnormally high fasting serum triacylglycerol (TG) levels (>150 mg/dl or >1.8 mM), is a
major risk factor for coronary heart disease, liver disease, and type-2 diabetes that
affects ～30% of U.S. adults [1,2]. Lowering blood TG translates into substantial
cardiovascular benefits [3]. Conventional therapies for hypertriglyceridemia include
dietary weight loss and exercise, dietary supplementation with fish oil or niacin, and drug
intervention, which may include fibrates or combined therapy with statins when LDLcholesterol is elevated. Although some improvement is noted with drug therapies [4–7],
serious associated side effects remain a concern [5, 8–10].
These impediments led us to examine the therapeutic potential of (R)--Lipoic acid
(LA), a naturally occurring cofactor with lipid regulating properties. LA is synthesized
enzymatically from octanoate in most prokaryotic and eukaryotic microorganisms as well
as plant and animal mitochondria. Although de novo synthesis provides LA needed for its

17

function of cofactor in mitochondria, it can also be absorbed from foods (leafy green
vegetables and red meats) and dietary supplements. There is strong evidence that orally
supplied LA elicits biochemical activities with potential therapeutic value against an
array of pathophysiological conditions, including diabetic polyneuropathies, ageassociated cardiovascular, cognitive, and neuromuscular deficits [11]. The TG-lowering
properties of dietary LA have recently been recognized, first in laboratory animals [12–
15] then in human [16, 17].
Despite these reports, the mechanism by which LA regulates blood TG is not
known and the degree to which LA can improve severe hypertriglyceridemia not well
documented. We showed previously that LA supplementation prevented the rapid rise in
blood plasma VLDL-TG that occurs between week 7 and week 9 of age in ZDF rats [14].
In the present study, we sought to determine the extent to which short-term dietary
supplementation with LA affects overt hypertriglyceridemia, and to identify the
molecular targets of LA. Results show that feeding LA to ZDF rats reversed
hypertriglyceridemia, lowered abdominal fat mass, repressed genes of long-chain fatty
acid and glycerolipid synthesis in the liver and adipose tissue, upregulated the production
of fibroblast growth factor 21 (FGF21), and upregulated specific PPARα target genes
involved in long- and medium-chain fatty acyl ester metabolism.

MATERIALS AND METHODS
Animals and diets
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Obese male Zucker rats (ZDF/GmiCrl-fa/fa, 7-week old) were purchased from
Charles River Laboratories and handled throughout in accordance with Institutional
Animal Care and Use Committee approved guidelines. The feeding study was designed
as an intervention trial where LA (3 g/kg diet, MAK Wood) is administered in the diet
after blood TG has become elevated. At this level of supplementation we estimate LA
intake to approximate 200 mg/kg body weight per day. Upon arrival, rats were acclimated
for two weeks in individual cages in a controlled environment (ambient temperature 22 ±
2 C, 12:12-h light–dark cycle) with free access to food (Purina 5008, 26.8% calories from
protein, 16.7% from fat, 56.4% from carbohydrates) and water. At 9 weeks of age, the
rats were randomly assigned to one of two treatments (Purina 5008 + LA or Purina 5008
pair-feeding) for two weeks. Throughout the trial, animals were given two-day feeding
rations between 1 and 3 pm and provided MilliQ water to drink. Food and water intake as
well as body weight were recorded every other day.

Blood plasma analyses
Three-hour fasted blood was collected at the beginning and end of the trial in
EDTA-coated tubes and plasma obtained by centrifugation at 12,000×g for 1 min and
stored at

－80

°C. Plasma TG was measured using the Serum Triglyceride Determination

kit (Sigma–Aldrich). NEFA and ketone bodies (3-β-hydroxybutyrate + acetoacetate) were
determined enzymatically by using commercial kits (Wako Diagnostics). Insulin and
FGF21 were measured by ELISA (Millipore).
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Tissue sampling
At 11 weeks of age, rats were anesthetized with inhalant isoflurane and pancreas,
liver, abdominal fat (epididymal + mesenteric + omental + retroperitoneal fat), small
intestine, and skeletal muscle (soleus and gastrocnemius) were quickly removed,
weighed, frozen in liquid N2, and stored at –80 °C.

Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolation from tissue using TRIzol and treated with DNase I. RNA
integrity was confirmed on an Agilent Bioanalyzer 2100. First strand cDNA was
synthesized with oligo(dT) and random primers using BioRad iScript. qRT-PCR was
performed on a BioRad CFX96 using SYBR Green supermix. Amplicon authenticity was
confirmed by melt curve analysis and agarose gel electrophoresis. PCR efficiencies were
assessed with serial dilutions of the template (0.001–100 ng cDNA/reaction) and 0.3 lM
of each primer, and plotting quantification cycle (Cq) vs. log amount of template. PCR
efficiencies between target genes and housekeeping genes were comparable, thus
unknown amounts of target in the sample were determined relative to cyclophilin A
(Ppia) and 60 S acidic ribosomal protein P0 (Rplp0). Primer sequences are shown in
Table 2.1.

Western blotting
Liver, skeletal muscle and adipose tissues were homogenized as previously
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described [14]. Commercial antibodies to FASN (BD Biosciences), ACC, phospho-ACC
(Ser 79), AMPK (clone 23A3), and phospho-AMPK (Thr 172, clone 40H9) from Cell
Signaling, α-tubulin (clone 6–11B-1, Sigma–Aldrich), and β-actin (clone AC-15, Sigma–
Aldrich) were used. Antibody binding was visualized using LiCOR IR Dye secondary
antibodies and Odyssey scanner.

Immunohistochemistry
Immunohistochemistry experiments were carried out to determine which endocrine
cells of the pancreas produce FGF21. To that end, anti-FGF21 (LifeSpan Biosciences,
LS-B5864), anti-glucagon (a-cells, Dako, A0565), and anti-pre/proinsulin (β-cells, Dako,
A0564) antibodies and formalin-fixed, paraffin-embedded pancreas specimens of ZDF rat
were used. Antibody to FGF21 was detected with anti-rabbit secondary (Vector, BA1000) and alkaline phosphatase staining kits (Vector AK-5000; Vector SK-5100), which
produced a fuchsia- or red-colored deposit. Antibody to glucagon and antibody to insulin
were stained using a horseradish peroxidase-based detection system (Dako LSAB+,
K0690) and 3,30-diaminobenzidine chromogen substrate (Dako DAB+, K3468), which
produced a brown precipitate. Tissues were also stained with a positive control antibody
(Factor VIII) to ensure that the tissue antigens were preserved and accessible for analysis.
The negative control consisted of performing the entire immunohistochemistry procedure
on adjacent sections in the absence of primary antibody. Slides were imaged with a DVC
1310C digital camera coupled to a Nikon microscope.
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Statistical analysis
Statistical significance was determined by unpaired two-tailed Student t-test with
Welch’s correction. All statistical tests were performed to the 5% significance level.

RESULTS AND DISCUSSION
The present study demonstrates that dietary supplementation with LA for two weeks
ameliorates whole-body lipid status in ZDF rats, a model of obesity and severe
hypertriglyceridemia. Using this model we showed previously that LA supplementation
prevented the rapid rise in blood plasma VLDL-TG that predictably occurs between 7 and
9 weeks of age [14]. In the present study, LA not only stopped the progression of
hypertriglyceridemia, but also normalized blood TG (Fig. 2.1). This situation is relevant
to the human situation where individuals seek treatment after hypertriglyceridemia is
diagnosed.
Initial and final body weights did not differ between treatments nor did weight gain,
food intake, and liver weight at the end of the trial (Table 2.2). LA lowered abdominal fat
mass (–2.4 g/rat, P < 0.05) and abdominal adiposomatic index (–0.5%, P < 0.05) (Table
2.2). At the end of the trial, all ZDF rats regardless of treatment were hyperinsulinemic
(10–12 ng insulin/ml). Dietary LA did not alter blood plasma NEFA concentrations,
which rose from 0.8 mM to 1.1 mM, suggesting active lipolysis in the adipose tissue
prevailed. It also suggests that the uptake by peripheral tissues of NEFA released from fat
deposits was not stimulated by LA. Plasma ketone bodies were not significantly different
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among treatment groups at the end of the trial (Pair-fed, 116 ± 18 lM; LA, 90 ± 10 lM).
As ketone bodies rise in the blood during fasting when glucose is not readily available,
the present data indicate that LA did not stimulate ketogenesis and both groups of animals
displayed comparable degree of fasting.
Since the diet used in the study is low in fat and high in carbohydrates, lipogenesis
from carbohydrates in the setting of overnutrition is stimulated in ZDF rats. Hence, the
changes observed in lipid status are explained primarily by postprandial changes to the
conversion rate of carbohydrates to fat. To ascertain the molecular targets of LA, gene
expression of enzymes involved in de novo fatty acid and TG syntheses was determined
(Fig. 2.2). In liver, feeding LA significantly repressed expression of Acly (–60%), Acaca
(–61%), Fasn (–50%), Gpam (–52%), Dgat2 (–46%), and Pnpla3 (–92%). Similarly, in
epididymal fat pad, mRNA levels of Acly (–38%), Acaca (–54%), Fasn (–57%), Gpam (–
44%), and Pnpla3 (–64%) were repressed or trended down in LA-fed animals. Decreases
in liver Acaca and Fasn expression translated into significant changes in protein levels of
ACC (–48%, P < 0.007) and FASN (–80%, P < 0.0002) (Fig. 2.3A). FASN abundance
was decreased by LA (although not significantly) in epididymal fat and gastrocnemius
muscle (Fig. 2.3B,C). The downregulation of Acly, Acaca, and Fasn in the liver and
adipose tissue of LA-fed animals is an illustration of repressed carbohydrate-to-fat
conversion. Operating simultaneously to lower blood TG, we showed that LA enhances
the clearance of TG-rich chylomicron-like particles [14]. The role of the liver vs. nonhepatic tissues in TG clearance is consequential as approximately one third of dietary
fatty acids absorbed by the small intestine and assembled in chylomicrons is taken up by
the liver [18]
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In addition to regulating fatty acid de novo synthesis and esterification to
glycerolipids, our data indicate that LA upregulated the gene expression of liver Acsm3,
Cpt1b, and Acot1 (Fig. 2.2). Through these enzymes, LA has the potential to modulate
cellular concentrations of medium- and long-chain fatty acids and their acyl-CoA
metabolites. ACSM3 catalyzes the formation of medium-chain fatty acyl-CoA (C4 to C11
in chain length) in mitochondria. This reaction serves two important functions that
oppose steatosis, (i) the bioactivation of medium-chain fatty acids into intermediates of βoxidation, (ii) the production of hexanoyl-CoA and octanoyl-CoA, which repress the
transcription of lipogenic genes Acaca and Fasn [19,20]. ACOT1 is a cytosolic enzyme
that hydrolyzes long chain acyl-CoA (C12 to C20 in chain length) to the free fatty acid
and CoA. Liver Acot1 expression was markedly stimulated upon treatment with PPAR
agonist Wy-14643 [21], suggesting ACOT1 participates in lipid disposal. Free fatty acids
generated in the cytosol by ACOT1 associate with fatty acid binding proteins (FABPs)
and translocate to the nucleus where they are ligands of nuclear receptors, PPARs and
HNF4 among others [22]. Thus, by converting acyl-CoA to free fatty acids, ACOT1
may influence gene transcription. Although dietary LA induced liver Cpt1b expression,
the absence of Cpt1a induction strongly suggests that the flux of long-chain fatty acylCoA through mitochondrial β-oxidation was not stimulated by LA. One explanation may
be that β-oxidation is already elevated in ZDF rats [23] thus further enhancement cannot
be achieved. Exacerbation of mitochondrial β-oxidation to maximum capacity is
perceived as detrimental in the obese and diabetic as incompletely oxidized fatty acids
that are being generated contribute to insulin resistance [24]. In contrast, approaches to
relieve mitochondria, such as through the depletion of malonyl-CoA decarboxylase (an
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enzyme that promotes β-oxidation by relieving malonyl-CoA-mediated inhibition of
CPT1a) have been shown to restore insulin sensitivity [25].
AMPK did not participate in LA’s TG lowering. Although AMPK was reportedly
activated by LA in rodent tissues [26,27] and linked to the decrease in blood and muscle
TG, LA feeding to ZDF rats decreased liver AMPK content (–62%, P < 0.0002) and
failed to alter AMPK phosphorylation (Fig. 2.3). AMPK activity, assessed by the
phosphorylation state of downstream target ACC (Ser79), did not change with LA.
Timmers et al. reported that LA supplementation could prevent lipid accumulation
associated with feeding a high-fat diet in Wistar rats independently of AMPK [28].
Disparity between studies is also attributed to the choice of animal model. AMPK activity
is diminished in liver and muscle of ZDF rats [29], due in part to the absence of leptindependent stimulation of AMPK [30,31]. Since feeding LA to leptin-resistant ZDF rats
mimicked some of the metabolic consequences of AMPK (i.e. Downregulation of fatty
acid esterification to form TG), an alternative mechanism independent of AMPK exists in
ZDF rats.
The hormone-like protein FGF21 modulates lipid and glucose metabolism with
potential therapeutic benefit for obesity-related metabolic disorders [32–35]. We report
that LA, a naturally occurring micronutrient incorporated to the diet at a concentration
comparable to LA intake considered safe in humans [11,36,37], upregulates FGF21
production. Blood plasma FGF21 increased 330% in LA-fed rats vs. pair-fed controls (P
< 0.0002, Fig. 2.4A). This observation coincided with the upregulation of liver Fgf21
expression (+174%, P < 0.03, Fig. 2.4B). When compared to the liver, Fgf21 expression
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was 2 to 5-fold lower in epididymal fat, and ～50-fold lower in distal ileum and soleus
muscle. We did not observe inducement of Fgf21 by LA in adipose, distal ileum, or
soleus, suggesting tissue specificity that may stem from LA hepatic metabolism. The
quality of pancreatic RNA did not permit quantification of Fgf21 mRNA in this organ.
However, FGF21 was detected immunologically in the endocrine pancreas of ZDF rats.
Double labeling with pre/proinsulin and glucagon resulted in co-localized staining within
insulin-producing β-cells (Fig. 2.4C). Weaker co-localized staining was focally present
with FGF21 in glucagon-positive α-cells, but individual cells also showed single
monochromatic staining for FGF21 or glucagon. The most intensely stained FGF21positive cells did not show significant co-localized staining with glucagon. Mechanism of
LA-induced FGF21 expression is not yet known. Li et al. showed that sodium butyrate
administered intraperitoneally to mice (500 mg/kg body weight) augmented Fgf21
expression and circulating levels in a PPARα-dependent manner [38]. Induction of liver
Fgf21 expression is required for normal activation of lipid oxidation and TG catabolism
[32,39]. Conversely, genetic deletion of Fgf21 results in hepatosteatosis and
hypertriglyceridemia [39]. The administration of recombinant FGF21 to obese rats and
mice increases fat utilization and energy expenditure, and reduces plasma TG, glucose,
insulin, and hepatic TG [32–34]. Reduced hepatic TG is accompanied by a decrease in
lipogenic gene expression of Acaca, Fasn, Gpam, Dgat2, stearoyl-CoA desaturase-1, and
fatty acid elongase-6, and stimulation of PPARα target genes [33,34]. Strikingly, feeding
LA to lean and obese rats replicates these metabolic effects [14,40].
Taken together, our findings suggest that LA increases pathways of fatty acid
oxidation while conjointly decreasing pathways of de novo production as a two-sided
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complementary mechanism for how LA feeding decreases TG burden. The study shows
that LA upregulates FGF21 production in the obese by inducing hepatic Fgf21
expression. FGF21 expression in liver and serum may mediate the beneficial phenotype
evoked by LA.
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Table 2.1. qRT-PCR primers used to quantify gene expression
Product
size (bp)
160

NM_016987.2

GTTACTCGTTTTGGGGGAAA
CAGCCCACACTGCCTGTA

298

NM_022193

Fasn

GTGGAAGACACTGGCTCGAA
TGGTACACTTTCCCGCTCAC

195

NM_017332.1

Gpam

CGTGGGAAGGTGTTGCTATT
CAGCAATTGCCTCTTGGACT

248

NM_017274

Dgat2

AACACGCCCAAGAAAGGTG
AGGGCAGATGCCTCCAGAC

303

NM_001012345

Pnpla3

GTCGGATGAGAGCATCTGG
TAATGGGCAGGAGGTTGCAG

113

XR_085887.2

Pparg

GACACAGACAAAACATCAGTGG
CTGTGTCAACCATGGTAATTTCTTG

156

NM_013124.3

Acsm3

CCAGCTGTGGGAAGCAGTAT
ACTCCAGATGGATTTGGTGGTT

180

NM_033231.1

Cpt1a

CCACAAATTACGTGAGTGACTGGTGG
CCAGAAGACGAATGGGTTTGAGTTCC

213

NM_031559

Cpt1b

GCTCATTTCCGGGACAAAGGCAAG
TTGGAGGTCTTGTTCCTTATGGGAC

163

NM_013200

Acot1

GGCCACCCTGAGGTAAAAGGA
TGGTTTCTCAGGATAGTCACAGG

194

NM_031315.1

Acox1

CAGCCCTACTGTGACTTCCA
ACCTGGGCGTATTTCATCAG

279

NM_017340.2

Fgf21

CCTGGAGCTCAAAGCCTTGA
AAACTGCAGGCCTCAGGATC

129

NM_130752.1

Ppia

CGAGCTGTTTGCAGACAAAG
GTGTGAAGTCACCACCCTGG

140

NM_017101.1

Rplp0

CTAGAGGGTGTCCGCAATGT
AGGAAGGCCTTGACCTTTTC

161

NM_022402

Gene

Sequence (5’3’) a

Acly

ATGCCCCAAGATTCAGTCCC
CCACTGAAGGCTCATCTCGG

Acaca

a

Shown as sense primer followed by antisense primer.

b

GenBank accession number.

GenBank b
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Table 2.2. Body weight, weight gain, food intake, adipose and liver weights in ZDF
rats at the end of the 2-week feeding trial

Weight gain (% of initial body weight) = [(final body weight – initial body weight)/
initial body weight]×100. IAA, abdominal adiposomatic index; IH, hepatosomatic index.
Data are shown as the mean ± SE of 8 rats/group. *P < 0.05 compared with the pair-fed
group.
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Figure 2.1. Time-courses of blood plasma TG (*P<0.001), insulin, non-esterified
fatty acids (NEFA), and ketone bodies (3-β-hydroxybutyrate + acetoacetate) in 3-h
fasted ZDF rats fed ± LA (n = 8).
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Figure 2.2. Transcriptional changes induced by LA. mRNA levels (expressed as % of
control pair-fed group, n = 8) of selected genes in liver, epididymal fat, and soleus
muscle. *P < 0.05,**P < 0.02. PF, pair-fed group.
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Figure 2.3. Lipoic acid represses FASN and ACC independently of AMPK.
Immunoblots and densitometry depicting the tissue contents of phosphorylated AMPKα
(pAMPKα, Thr 172), total AMPKα (sum of AMPKα1 and AMPKα2), phosphorylated
ACC (pACC, Ser 79), total ACC (ACC1/2), FASN, and β-actin or α-tubulin as loading
control. *Denotes statistical significance (n = 8); liver AMPKα, P < 0.0002; liver ACC, P
< 0.007; liver FASN, P < 0.0002. PF, pair-fed group.
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Figure 2.4. Lipoic acid induces FGF21 production. (A) Temporal changes in blood
plasma FGF21 showing a 330% increase in LA-fed animals at the end of the trial (P <
0.0002, n = 8). (B) Relative Fgf21 mRNA levels in 125 ng total RNA of each tissue, and
normalized to housekeeping gene Ppia. Data represent the mean + SEM for 8 rats/group
for liver (*P < 0.03), adipose, and soleus muscle; 4 rats/group for ileum. (C)
Immunochemical detection of FGF21 in pancreatic islets showing strong co-localization
within insulinpositive β-cells. Data is representative of two rats fed LA.
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CHAPTER 3

ELUCIDATE THE MECHANISM BY WHICH (R)-α-LIPOIC
ACID UP-REGULATES FGF21 GENE EXPRESSION

INTRODUCTION
In Chapter 2, we report that naturally occurring dietary compound (R)--lipoic acid
(LA) stimulates liver Fgf21 expression (+174%) and blood FGF21 levels (+330%) and
replicates the adaptive metabolic response to fasting supported by FGF21 in vivo. In
particular, LA reversed hypertriglyceridemia, lowered abdominal fat mass, repressed
genes of long-chain fatty acid and glycerolipid synthesis in the liver and adipose tissue,
and upregulated specific PPAR target genes involved in long- and medium-chain fatty
acyl ester metabolism [1]. The potential impact of this work is that LA may prove to be a
safe and affordable means to stimulate FGF21 production.
Based on this research, we hypothesize that FGF21 mediates the lipid lowering
properties of LA (Fig. 3.1). Through this original work, we seek to shift current clinical
practice by building a case for LA as a dietary inducer of endogenous FGF21 and a nonprescription means to treat FGF21-responsive metabolic disorders. Elucidating the novel
mechanism by which LA lowers TG will stimulate interest in its therapeutic use and
justify further research on potential additive or synergistic effects of combined therapy
with LA in lipid metabolic disorder.
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We now seek to determine the precise mechanism of induction of the FGF21
promoter by this dietary molecule. It means to identify the regions of the promoter that
respond to LA and DHLA [2]. Since FGF21 may be regulated via an alternative distal
promoter P1 (retrieved from the Transcriptional Regulatory Element Database, TRED),
proximal promoter P2 may not account for full FGF21 inducibility and justifies the
survey of a ~5,000-bp genomic DNA region that includes FGF21 distal promoter and
spans clusters of acetylated histones and DNase hypersensitivity sites (Fig. 3.6). To this
end, we have developed the FAIRE (Formaldehyde-Assisted Isolation of Regulatory
Elements) assay to isolate regulatory regions that overlap to a large degree with DNase I
hypersensitivity regions and identify nucleosome-depleted regions of chromatin by qPCR
[3,4,5].
With this molecular tool, we plan to interrogate human FGF21 promoter regulation
from HepG2 hepatocellular carcinoma cells under fed and starved states and in the
presence of LA and DHLA. Our results will provide new insights into how nutrientresponsive transcription factor binding sites regulate FGF21.

MATERIALS AND METHODS
HepG2 cells
HepG2 cells were cultured in DMEM (5.5 mM glucose) supplemented with 10%
fetal bovine serum (FBS) and 0.25X antibiotics/antimycotics to 40-50% confluence and
used thereafter for the experiments. We conducted two experiments. Experiment 1
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evaluated the inducibility of FGF21 upon serum withdrawal as an attempt to replicate
FGF21 induction seen in vivo during starvation. To that end, HepG2 cells were cultured
in the absence or presence of FBS as described in Figure 3.2 (Experiment 1). HepG2 cells
continued to proliferate and maintain their morphology in absence of FBS. Serum
withdrawal also eliminated potential confounding factors brought about by constituents
found in FBS (e.g. growth factors, cytokines) with which the compounds of interest
(dietary dithiols) may have unintended interactions. In Experiment 2, HepG2 cells were
grown in the presence of LA (50 µM), DHLA (50 µM), or DMSO control for up to 48
hours in the absence of FBS, according to the protocol described in Figure 3.2. The final
concentration of DMSO was 0.1%, a concentration that is widely accepted as being inert
to cells, including HepG2 cells.

Abundance of FGF21 mRNA by quantitative Real-Time PCR (qRT-PCR)
HepG2 total RNA was extracted at the 0, 12, 24, 36 and 48-hour time points by
using BioRad Aurum kit, DNase I treated and quantified by NanoDrop. RNA integrity
was confirmed by using Agilent Bioanalyzer 2100. First strand cDNA was synthesized
with oligo(dT) and random primers using BioRad iScript. qRT-PCR was performed by
using a BioRad CFX96 and SYBR Green supermix according to the manufacturer’s
instructions. FGF21 mRNA was normalized to housekeeping gene cyclophilin A (PPIA).
Primer sequences are shown in Table 3.1.
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FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements)-qPCR
The FAIRE assay is used to isolate active regulatory DNA loci through the identification
of nucleosome-depleted region (‘open chromatin’), which is less efficiently cross-linked
to protein and will segregate to aqueous phase during phenol/chloroform extraction. The
purified input control HepG2 DNA and FAIRE DNA will later be detected by qPCR.
Input control DNA and FAIRE DNA are all produced from HepG2 cells according to the
FAIRE method in Figure 3.3. For our purpose, HepG2 DNA will be isolated at the 48hour time point in Experiment 1 and at the 36-hour time point in Experiment 2. Mapping
the response of the FGF21 promoter (chromosome 19) requires the design and validation
of a collection of primer pairs whose qPCR products cover the ~5,000-bp region of
interest. To that end, 25 primers pairs specific for human FGF21 promoter (PPs,
overlapping between two adjacent PPs) were designed and validated.

Statistical analysis
Statistical significance was determined with the unpaired two-tailed Student t-test
with Welch’s correction (Experiment 1), or the Kruskal-Wallis test followed by Dunn’s
multiple comparison test (Experiment 2). All statistical tests were performed to the 5%
significance level.

RESULTS AND DISCUSSION
Effect of serum starvation on FGF21 transcription in HepG2 cells
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Serum withdrawal induced a marked increase in FGF21 mRNA abundance (Fig.
3.4). The induction was significant from 24 hours (+5,530% vs. 0 hour) to 48 hours
(+12,460% vs. 0 hour) after serum removal. In contrast, the reintroduction of serum (10%
FBS) at 24 hours reversed the induction and brought FGF21 mRNA levels back down to
pre-experimental concentrations. Housekeeping gene, PPIA, was not markedly affected
by serum manipulation and remained highly expressed at all time points. The absence of
serum for 48 hours did not stop HepG2 cells from proliferating. Cell confluence was not
noticeably different among +/- serum treatments.

Effect of LA and DHLA on FGF21 transcription in serum starved HepG2 cells
Both LA and DHLA induced FGF21 mRNA levels when compared to vehicle
control (Fig. 3.5). DHLA-mediated induction (+900%, P<0.019) of FGF21 vs. DMSO
control was stronger than that of LA (+670%, P<0.024) at 36 hours. FGF21 induction by
the dithiols was not significant at 48 hours, suggesting the induction was transient.
FGF21 mRNA levels in DMSO controls at 36 hours were markedly different than those
at 48 hours. The reason for this change is not entirely clear, it may be linked to the
transient effect of the dithiols. Housekeeping gene, PPIA, was not markedly affected by
the treatment and remained highly expressed at all time points.

Design and validation of FAIRE-qPCR primer pairs
The sequences of the 25 primer pairs are shown in Table 3.2. The authenticity of the
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qPCR products generated with primers was confirmed by melt curve analysis and agarose
gel electrophoresis. qPCR efficiencies were assessed with 5-fold serial dilutions of
HepG2 DNA and plotting quantification cycle (Cq) versus log amount of template.
Efficiency curves (EC %) were between 89% and 114% (Fig. 3.7). The 25 qPCR
products covered 4,573 bp of FGF21 promoter (Fig. 3.8) with some overlap.

Taken together, our findings in HepG2 cells treated with LA and DHLA reproduced
the induction of hepatic FGF21 gene expression seen in LA-fed animals. Our data
indicating that DHLA induced FGF21 mRNA levels with higher potency than LA suggest
that DHLA may the relevant form of -lipoic acid in this process. Experimental evidence
supports this view. Indeed, studies have shown that cells and tissues enzymatically
convert LA into DHLA, and the conversion to DHLA is critical to support biological
effects [6]. Attempts to enrich cells or mitochondria with exogenous LA using a
triphenylphosphonium-conjugated lipoyl derivative showed that although the lipoyl
conjugate accumulated in cells and mitochondria, it was not protective against a range of
stressors as a consequence of its poor enzymatic reduction to dihydrolipoyl conjugate
caused by steric hindrance. LA was protective after reduction to DHLA, a reaction
catalyzed by thioredoxin reductase and glutathione reductase in the cytosol, and
dihydrolipoyl dehydrogenase in mitochondria.
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Table 3.1. Primer sequences for determining FGF21 coding mRNA by qRT-PCR
Human gene
FGF21

PPIA

Primer

Sequence (5’3’) a

Tm b

F1

GGGAGTCAAGACATCCAGGT

60.0°C

R1

GGCTTCGGACTGGTAAACAT

60.0°C

F1

TTCATCTGCACTGCCAAGAC

56.2°C to 60.7°C

R1

TGTCCACAGTCAGCAATGGT

56.2°C to 60.7°C

a

Shown as sense primer followed by antisense primer.

b

Appropriate annealing temperature.
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Table 3.2. Sequences of the 25 primer pairs designed for FAIRE-qPCR assay

Product

qPCR protocol b

PPs

Sequence (5’3’) a

PP1

GTGGCACATGTCTGTGGTCT
CGAGATTCCTTCAGGAAAGGT

193

isothermic qPCR

PP2

ATAGCACCGCTGACTGCAC
ACCTCTGTGGTGGATTTTGC

216

isothermic qPCR

PP3

CTTCCACCAGCCTGTTTCTC
GGACCCAGGAACAACTCCTT

244

TD PCR

PP4

GAGGTGGCGGAGATTCCTA
AAAAGCGGACTGTGGATCTG

162

isothermic qPCR

PP5

CAGATCCACAGTCCGCTTTT
CTCCACCTTCCAGCCATC

230

TD PCR

PP6

GATGGCTGGAAGGTGGAG
TGGCACCGGAAGAGAGAG

280

TD PCR

PP7

GGTGCCAGGGCTTAGAGTC
AGCCTGGCAAACAGGTTCT

159

TD PCR

PP8

GGGATGGAGAACCTGTTTGC
GCAGTGCAGGTCTGGAAAGT

207

TD PCR

PP9

CCTTTTGGGGAATTCTAGGG
GCCTTGGACCAGAGAAAATG

203

isothermic qPCR

PP10

GCATTTTCTCTGGTCCAAGG
GGTCTCTGCGTCTTGATGGT

207

isothermic qPCR

PP11

CTACCATCAAGACGCAGAGACC
TGCAGAGAAGAAAACGCTGACA

218

isothermic qPCR

PP12

GCAGAAAGAGAAGGCAGCAT
ACACCTTCTCCTGCCTCAC

286

TD PCR

PP13/14

TGAGGCAGGAGAATGGTGTG
AGTCATCCTGCTGTGCTGTG

238

TD PCR

PP15

ACCATTGAAGCACAGCACAG
TTCTGTCACACCGGCATAAG

213

isothermic qPCR

PP16

TCGTGGTCTGCTGAGTAACG
AACAACCGGTGGGTATAGGG

167

TD PCR

size (bp)
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PP17

TATACCCACCGGTTGTTTCC
AATGGGAGGGTCAGTCTGTG

238

isothermic qPCR

PP18

AATCCTTCCCCACAGACTGA
GGGAGCCTGGACTCCTAAGT

193

isothermic qPCR

PP19

CCAGACCCTTCTGCTCACAC
AGGGAGCTTTGGTCTGGACT

230

TD PCR

PP20

AGGAGTCCAGACCAAAGCTC
ACCCAGAGGGAAGACAGGTT

247

isothermic qPCR

PP21

AGCCAACCTGTCTTCCCTCT
CAACCTCATCTGTCCCTGCT

218

isothermic qPCR

PP22

ATGTCCAGGGTCTGAGCATC
ATGCAGATCACGCAGAACAA

232

isothermic qPCR

PP23

TCTTGTTCTGCGTGATCTGC
TGTAACCTGGGGTCCTTTCA

228

isothermic qPCR

PP24

ACCCCAGGTTACATCATCCA
CAGCTGACAGAACACCCTTG

177

isothermic qPCR

PP25

TCTGTCAGCTGAGGATCCAG
GCACAGAAACCCACAGTCCT

203

isothermic qPCR

PP26

GGACTGTGGGTTTCTGTGCT
ATCCTCCCTGATCTCCAGGT

165

isothermic qPCR

a

Shown as sense primer followed by antisense primer.

b

qPCR protocol employed for the validation of primer pairs. TD qPCR, Touch-down

qPCR.
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Figure 3.1. Hypothesis that fibroblast growth factor-21 (FGF21) is the missing link
in LA-mediated disposal of fat in target tissues. TF = transcription factor.
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Experimental 1: Effect of serum starvation on FGF21 transcription in HepG2 cells

Experiment 2: Effect of LA & DHLA on FGF21 transcription in serum-free HepG2 cells

Figure 3.2. Experimental design of HepG2 cell studies
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Figure 3.3. FAIRE assay protocol. [Adapted from Simon et al. 2012].
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Figure 3.4. Time-course of FGF21 mRNA abundance as affected by the presence or
absence of serum (Experiment 1). reFBS indicates that FBS (10% final concentration)
was reintroduced at 24 hours. Serum withdrawal strongly induced FGF21 mRNA steadystate levels at 24, 36 and 48 hours. The reintroduction of serum blocked FGF21 induction
at the 36 hours (*P < 0.0007) and 48 hours (*P < 0.0001) time points (n=6).

PPIA mRNA levels

51

120000

House-keeping Gene

100000
80000
60000
40000

a

20000
0
0

12

24

36

48

a
b

Figure 3.5. Time-course of FGF21 mRNA abundance as affected by LA and DHLA
(Experiment 2). DHLA (+900%, P<0.019, n=6) and to a lesser extent LA (+670%,
P<0.024, n=6) significantly increased FGF21 mRNA levels at 36 hours vs. DMSO
control. Data not sharing a common letter at a given time point are significantly different.
Cells were grown in the absence of serum from the 0-hour time point. DMSO, LA (50
µM) or DHLA (50 µM) were added at 24 hours.
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Figure 3.6. Human FGF21 gene and promoter structure, and positioning of
promoter P1 and P2, the ~5,000-bp region to survey, and acetylated histone marks
found near active regulatory elements.
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Figure 3. 7. The qPCR efficiency curves (EC %) of the 25 primer pairs. Horizontal
axis: Log Starting Quantity; Vertical axis: Cq value.
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Figure 3. 8. Sequence (4,573 bp) of the human FGF21 5’ UTR (chromosome 19).
Starts @ 49,255,156
Ends @ 49,259,728
AGAGAGGCTGGAGGGTC = start of predicted promoter P1
AGGTTGGCCCACGGCCA = start of predicted promoter P2
CTGTCAGCTGAGGAT…GCCGCCGAAA = 385 bases of Exon 1 of human FGF21

TGAGATCATGCCATTACACTCCAGCCTGGGCAACAAGAGTGAAACTCCGTCTC
CAAAAAAAAATAAATAAAATTAGCTTGGCATGGTGGCACATGTCTGTGGTCTC
AGCTACACCGGATGCTAAGGCGGGAGGATCCCCGGAGCTCACAATGAGCCGC
GATAGCACCGCTGACTGCACTCCAGCTTGCGCGACAGAGAGGGACCCTGTCTT
AAAAAAAAAAAAAAAAAAAAAAAAAGAAAGTGGTCCAGGTTCCTACACCTT
TCCTGAAGGAATCTCGAGTCTCCCCTCCTGTAAGTTCCGCTGATACTGGACTCT
TCCACCAGCCTGTTTCTCAGGAGTACCTGTCTGTGAGGCGCAAAATCCACCAC
AGAGGTGGTGATGGGAAACGATAGTTCAAGTAAAACAAGAGAGGCTGGAGG
GTCAGGAGCGGAAGGAGCATCTTGGTTCCTGGAGGAGTAATGGCTGGGGAGG
TGGCGGAGATTCCTAGGGCCTTAGGAAGACCTGGAGAAGAGGTTGGGGGTGC
ACCTCCTGGTTCTGAAGGAGTTGTTCCTGGGTCCCAGGAACAACTGAGTGGG
GCAGTCCCCACTTACCCGAGCTGCTTGCAGGTGGCAGATCCACAGTCCGCTTT
TCGTGGCCGGAGCGCACCCTCCGCAAAGGCAGGCCACATCCGGCCGCCCCTG
GAACGCCAGGCGTCCGGCTATCCGGCCCGGCAGCCCTCCCCTCCGCGCAGCCT
GTCCGGACTGGCAGCGAGGGCTTGGGGAGGAGAGGAAGGAGAGGGCGCGGC
CGGGAGTCTCGCAGCGTCCGCCCTCCCGGGCCGGGCGGATGGCTGGAAGGTG
GAGCCCCGCCCGTCACTTGGCGCCGAGCCCCAGCGCCAGGGGCTAAGGCGAT
GGCCCCTGGGCCCACCGCTCCCCAGATCGGGGATGCAGGGGACCGCGCCCTG
CCCCTCCGCCCCGTCATTGACCTGCGCGAAGGCTTCACCCAGGGCAGGCTACC
TGGCTTCTGAGCAGCCGCAGCATCATTGCGTGGACCAGGAGACGGAGCGCCC
AGTTGCAATGCTGGAGCCGGGAGGTCCAATCCGCCGCCCTCTCTCTTCCGGTG
CCAGGGCTTAGAGTCGGCCCCCGACACCTGGGTGCTTCGAGCCTGGCCACGC
CCCAGCGGCTGGGCAGGGCCCCCGCACCTGGTCCCGGCGAGTGGAGCGATCG
TCCGCCCTCTGCCGCGTCCTCCTGGGGGATGGAGAACCTGTTTGCCAGGCTGC
CGCCGGAGCGCGCGAGGGCCTCCAGCCTGCAGGTGCTCCCGCGCCCACCAGG
GTCTCCGATCTCCCACACCCCCCGCCTCACCGTCCACACTCAAATTCCAGAAT
CCCAGCCCCTAGTCACTCCTTTTGGGGAATTCTAGGGTCCCGTGCCAAACTGC
TACTTTCCAGACCTGCACTGCACGAAGGCAACCATTCCAAGGCTGGAGACCG
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GAGTGGAACAGGGTCTGTTTCCCACGCCGTCAGCGGGGGCCGTGGCTGCCGG
CGCCAGAGACAAAGGCCTCTGCCCGCTTGTCACCTAATTAAAGCATTTTCTCT
GGTCCAAGGCCCACCTCCAGCATCGCCAACCCCGAGCAGGGCAGGCTAACGT
AGGGTCCAGCCCTACGGGGCTTTGCGGGTGGGTGTTCTTCCCCTGTGAGGAG
AGGAGAGATTGTAAGAAATAAAGACACAAGACAAAGAGATAAAGAGAAAAC
AGCTGGGCCCGGGGGACCACTACCATCAAGACGCAGAGACCGGTAGTGGCCC
CGAATGGCTGGGCGCGCTGATATTTATTGTATACAAGACAAGGGGGGGCAGGA
TAAGGAGGGTGAGTCGTCCAAATGACTGATAAGGTCAAGCAAGTCACGTGAT
CATGGGACAGGGGGCCCTTCCCTTTTAGGCAGCCGAAGCAGAAAGAGAAGGC
AGCATATGTCAGCGTTTTCTTCTCTGCACTTATAAGAAAGATCAAAGACTTTAA
GACTTTCACTATTTCGGGCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACT
TTGGGAGGCTGAGGCGGGCGGATCACAAGGTCAGGAGGTGGAGGCCATCCTG
GCTAACACGGTGAAACCCTGTCTCTACTAAAAATACAAAAAATTATCCGGGCG
CGTGGTGGAGGGCGCCTGTAGTCCTAGCTATTTGGGAGGGTGAGGCAGGAGA
ATGGTGTGAACCCAGGAGGCGGAGATTGCAGTGAGCCGAGATCACGCCACTG
CACTCCAGCCTGGGGGACAGAGCGAGACTCCGCCTCAAAAAAAAAAAAAAA
AAGGCTTTCACTATTTCTTCTACCGCTATCTACTACGAACTTCAAAGAGGAACC
AGGAGTACGGGAGGAAAATGCAAGAGGACAAGGAGCGTGACCATTGAAGCA
CAGCACAGCAGGATGACTGCGGGCAGGCCTAGATAATACCCAGCCTCCCACA
AGAAGCTGGTGGAGCAGAGTGTTCCCTGACTCCTCCAAGAAAAGGAGATTCC
CTTTCGTGGTCTGCTGAGTAACGGGTGCCTTCCCAGACACTGGCGTTCCCGCT
TGACCAAGGAGCCCTCAAGAGGCCCTTATGCCGGTGTGACAGAAGGCTCACC
TCTTGCCTTCTAGGTCACTTCTCACAATGTCCCTTCAGTACCTGACCCTATACC
CACCGGTTGTTTCCTGGTTATATTAGTTATACAACAAAGAATAAAAGTAATAGCT
AATGATTAATAATGTTTACACTAATGATTGATACTGTCCATGATCATCTCTATATC
TAATTTGTATGATAACTATTCTTATTCTAACTATTTTCTTTATTATACTGAAACAGT
TTGTGCCTTCAGTCTCTTGCCTCGGCACCTGGGTAATCCTTCCCCACAGACTGA
CCCTCCCATTCAAGATACATCAATGTCAAAGACTCAGGAGTTTGACTTGATTCC
CAGAAGTTTAACCATCATCTCCCCAGGCTCGGGACTCCCAGCACCCAGACCCT
TCTGCTCACACCCAGCAGTCCAGGCCCCCAGACCCTCCTCCCTCAGACTTAGG
AGTCCAGGCTCCCGGCCCCTCCTTCCTCAGACCCAGGAGTCCAAGCCCCCTGC
CCCTCCTTCCTCAGACCCAGGAGTCCAGGACCCCAGCCCCTCCTTCCTCACAC
CCACGAGTCCAGATCCCTAGCCCCTACTCCCTCAGACCCAGGAGTCCAGACCA
AAGCTCCCTCCTCCCTCAGACCCAGGAGCCCAAGTTCCCCAGCCCCTCCTCCC
TCAGATCCAGGAGTACAGGCCCAGACCCTCCTCCCTCAGACCCAGGAGTCCA
GGCCCCCCACCCCTCCTCCCTCAGACCCAGGAGTCCAGAGCCCCAGCCCTCCT
CCCTCAGACACAGAAGGCCTACCCTTGCACCCTTAGGGGCTCCAGGAAATTAG
CCAACCTGTCTTCCCTCTGGGTGCCCACTCCAGGGCCTGGCTTGGCTGCCAAC
TCCAGTCAGGGACTTTCAGCCACCCCTCCCCCCAGGTTATTTCAGGAGCACCT
GCCTGGGCCTGGGATGGCTTCTCTGGTGAAAGAAACACCAGGATTGCATCAG
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GGAGGAGGAGGCTGGGATGTCCAGGGTCTGAGCATCTGAGCAGGGACAGATG
AGGTTGAGGTTGGCCCACGGCCAGGTGAGAGGCTTCCAAGGCAGGATACTTG
TGTCTCAGATGCGGTCGCTTCTTTCATACAGCAATTGCCGCCTTGCTGAGGATC
AAGGAACCTCAGTGTCAGATCACGCCCTCCCCCCAAACTTAGAAATTCAGATG
GGGCGCAGAAATTTCTCTTGTTCTGCGTGATCTGCATAGATGGTCCAAGAGGT
GGTTTTTCCAGGAGCCCAGCACCCCTCCTCCCTCCGACTCAGGTGCTTGAGAC
CCCAGATCCTTCTCTCTGAGACTCAGGAATGTGGGCCCCCAGCCCCTTTCACC
TGGGTCCCAGCTAACCCGATCCTCCCCTCCCTCATCCCCTAGACCCAGGAGTC
TGGCCCTCCATTGAAAGGACCCCAGGTTACATCATCCATTCAGGCTGCCCTTGC
CACGATGGAATTCTGTAGCTCCTGCCAAATGGGTCAAATATCATGGTTCAGGCG
CAGGGAGGGTGATTGGGCGGGCCTGTCTGGGTATAAATTCTGGAGCTTCTGCA
TCTATCCCAAAAAACAAGGGTGTTCTGTCAGCTGAGGATCCAGCCGAAAGAGG
AGCCAGGCACTCAGGCCACCTGAGTCTACTCACCTGGACAACTGGAATCTGGC
ACCAATTCTAAACCACTCAGCTTCTCCGAGCTCACACCCCGGAGATCACCTGAG
GACCCGAGCCATTGATGGACTCGGACGAGACCGGGTTCGAGCACTCAGGACTG
TGGGTTTCTGTGCTGGCTGGTCTTCTGCTGGGAGCCTGCCAGGCACACCCCAT
CCCTGACTCCAGTCCTCTCCTGCAATTCGGGGGCCAAGTCCGGCAGCGGTACC
TCTACACAGATGATGCCCAGCAGACAGAAGCCCACCTGGAGATCAGGGAGGAT
GGGACGGTGGGGGGCGCTGCTGACCAGAGCCCCGAAA
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CHAPTER 4

CONCLUSION

Recent research work in metabolism and nutrition has shed new light on the ability
of FGF21 to improve metabolic disorders related to glucose and lipid homeostasis and on
the inducibility of the FGF21 gene by bioactive food compounds [1]. Research into the
metabolic effects and molecular mechanism of action of -lipoic acid as a relevant
natural inducer of FGF21 production has been pursued in this thesis. Our research shows
that (R)--lipoic acid stimulated liver FGF21 gene expression (+175%) and blood FGF21
levels (+330%) and replicated the adaptive metabolic response to fasting supported by
FGF21 in vivo. Further studies of the regulation of the FGF21 promoter will have
implications both in basic research and in clinical setting.
In recent years, there has been a significant push toward the development of new
therapeutics that target lipid risk factors other than hypercholesterolemia, such as
hypertriglyceridemia. There is a growing interest in the therapeutic potential of -lipoic
acid against dyslipidemia. Seven clinical trials on the topic were published over the
previous three years out of a total of 17 clinical trials on -lipoic acid. Careful review of
these studies indicates -lipoic acid (600 mg/day) safely lowers blood triacylglycerol
once triacylglycerol have become elevated [2-8]. As of now, however, no clinical trial
with -lipoic acid in hypertriglyceridemic subjects has been conducted in the United
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States. Before clinical trials with -lipoic acid can be initiated, the molecular targets and
cellular signaling of -lipoic acid will need to be uncovered.
The molecular mechanism of -lipoic acid proposed herein supports a shift from
the current paradigm that -lipoic acid acts as an antioxidant to the new concept that lipoic acid regulates gene transcription. Although historically recognized as an
antioxidant able to reduce various oxidized targets (including other antioxidants), lipoic acid does not act as a traditional antioxidant here. At the doses ingested from a
supplemented diet and because it is very rapidly metabolized, -lipoic acid does not
accumulate to sufficient cellular levels (low M) to have a lasting impact similar to that
of traditional antioxidants (e.g., ascorbate or tocopherol) [9, 10]. Rather, -lipoic acid
transiently stimulates cell signaling and transcription pathways relevant to lipid
homeostasis [11]. Experimental evidence collected in recent years, including our own,
support a new yet definable mechanism of -lipoic acid action that ultimately results in
its universal lipid-lowering effect.
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